EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Exploring the tumor genomic landscape of aggressive prostate cancer by whole‐genome sequencing of tissue or liquid biopsies

Simone Weiss, Philippe Lamy, Maria Rusan, Maibritt Nørgaard, Benedicte Parm Ulhøi, Michael Knudsen, Christine Gaasdal Kassentoft, Leila Farajzadeh, Jørgen Bjerggaard Jensen, Jakob Skou Pedersen, Michael Borre, Karina Dalsgaard Sørensen iD

International Journal of Cancer · 15.07.2024 · 155 (2) · 298-313

DOI: 10.1002/ijc.34949 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, online erschienen am 11.04.2024. Verfasst von Simone Weiss und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark. Hauptthemen laut MEDLINE: Whole Genome Sequencing, Prostatic Neoplasms, Circulating Tumor DNA, Biomarkers, Tumor. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Independent Research Fund Denmark, The Novo Nordisk Foundation, Aarhus University, Graduate School at Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Treatment resistance remains a major issue in aggressive prostate cancer (PC), and novel genomic biomarkers may guide better treatment selection. Circulating tumor DNA (ctDNA) can provide minimally invasive information about tumor genomes, but the genomic landscape of aggressive PC based on whole‐genome sequencing (WGS) of ctDNA remains incompletely characterized. Thus, we here performed WGS of tumor tissue ( n = 31) or plasma ctDNA ( n = 10) from a total of 41 aggressive PC patients, including 11 hormone‐naïve, 15 hormone‐sensitive, and 15 castration‐resistant patients. Across all variant types, we found progressively more altered tumor genomic profiles in later stages of aggressive PC. The potential driver genes most frequently affected by single‐nucleotide variants or insertions/deletions included the known PC‐related genes TP53 , CDK12 , and PTEN and the novel genes COL13A1 , KCNH3 , and SENP3 . Etiologically, aggressive PC was associated with age‐related and DNA repair‐related mutational signatures. Copy number variants most frequently affected 14q11.2 and 8p21.2, where no well‐recognized PC‐related genes are located, and also frequently affected regions near the known PC‐related genes MYC , AR , TP53 , PTEN , and BRCA1 . Structural variants most frequently involved not only the known PC‐related genes TMPRSS2 and ERG but also the less extensively studied gene in this context, PTPRD . Finally, clinically actionable variants were detected throughout all stages of aggressive PC and in both plasma and tissue samples, emphasizing the potential clinical applicability of WGS of minimally invasive plasma samples. Overall, our study highlights the feasibility of using liquid biopsies for comprehensive genomic characterization as an alternative to tissue biopsies in advanced/aggressive PC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Whole Genome SequencingProstatic NeoplasmsCirculating Tumor DNABiomarkers, TumorHumansMaleAgedLiquid BiopsyMiddle AgedDNA Copy Number VariationsMutationAged, 80 and overGenomics

Stichwörter der Autor:innen

ctDNAgenomicsliquid biopsiesprostate cancerwhole‐genome sequencing

Substanzen

Circulating Tumor DNABiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark.
  • Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
  • Department of Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark.
  • Department of Pathology, Aarhus University Hospital, Aarhus, Denmark.
  • Department of Biomedicine, Aarhus University, Aarhus, Denmark.
  • Department of Urology, Gødstrup Hospital, Gødstrup, Denmark.

ORCID-Profile: Karina Dalsgaard Sørensen

Förderung

  • Independent Research Fund Denmark
  • The Novo Nordisk Foundation
  • Aarhus University, Graduate School at Health
  • The Danish Cancer Society
  • Danmarks Frie Forskningsfond
  • Novo Nordisk Fonden
  • Aarhus Universitet
  • Kræftens Bekæmpelse

Zitieren

APA

Weiss, S., Lamy, P., Rusan, M., Nørgaard, M., Ulhøi, B. P., Knudsen, M., Kassentoft, C. G., Farajzadeh, L., Jensen, J. B., Pedersen, J. S., Borre, M., & Sørensen, K. D. (2024). Exploring the tumor genomic landscape of aggressive prostate cancer by whole‐genome sequencing of tissue or liquid biopsies. International Journal of Cancer, 155(2), 298-313. https://doi.org/10.1002/ijc.34949

Vancouver

Weiss S, Lamy P, Rusan M, Nørgaard M, Ulhøi BP, Knudsen M, et al. Exploring the tumor genomic landscape of aggressive prostate cancer by whole‐genome sequencing of tissue or liquid biopsies. International Journal of Cancer. 2024;155(2):298-313. doi:10.1002/ijc.34949

BibTeX
@article{Weiss2024,
  author = {Weiss, Simone and Lamy, Philippe and Rusan, Maria and Nørgaard, Maibritt and Ulhøi, Benedicte Parm and Knudsen, Michael and Kassentoft, Christine Gaasdal and Farajzadeh, Leila and Jensen, Jørgen Bjerggaard and Pedersen, Jakob Skou and Borre, Michael and Sørensen, Karina Dalsgaard},
  title = {Exploring the tumor genomic landscape of aggressive prostate cancer by whole‐genome sequencing of tissue or liquid biopsies},
  journal = {International Journal of Cancer},
  year = {2024},
  volume = {155},
  number = {2},
  pages = {298--313},
  doi = {10.1002/ijc.34949}
}
Kostenlos starten →